Publications by authors named "Jeffrey Botbyl"

Claim this Profile
A
Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.
Brian G Rash, Kevin N Ramdas, Nataliya Agafonova, Eric Naioti, Lisa McClain-Moss, Jeffrey Botbyl

Nat Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Parallel-group Study of Digital Gut-directed Hypnotherapy vs Muscle Relaxation for Irritable Bowel Syndrome.
Sameer K Berry, Rani Berry, David Recker, Jeffrey Botbyl, Lucy Pun

Clin Gastroenterol Hepatol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting drug-drug and drug-gene interactions in a community pharmacy population.
Daniel Dowd, Gabriela Williams, Daniel VanDorn, Stephen Clarke, David S Krause, Jeffrey Botbyl

Am J Manag Care· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of a digital therapeutic for substance use disorder: Secondary analysis of data from a NIDA clinical trials network study.
Yuri A Maricich, Edward V Nunes, Aimee N C Campbell, Jeffrey D Botbyl, Hilary F Luderer

Subst Abus· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder.
Yuri A Maricich, Warren K Bickel, Lisa A Marsch, Kirstin Gatchalian, Jeffrey Botbyl

Curr Med Res Opin· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
Joanne Brady, Pippa Corrie, Ian Chau, Raghunadharao Digumarti, Laurel M Adams, Jeffrey Botbyl

Invest New Drugs· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients.
Kevin M Koch, Young-Hyuck Im, Sung-Bae Kim, Ander Urruticoechea Ribate, Joe Stephenson, Jeffrey Botbyl

Clin Pharmacol Drug Dev· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors.
Cathrine L Denton, Elisabeth Minthorn, Stanley W Carson, Graeme C Young, Lauren E Richards-Peterson, Jeffrey Botbyl

J Clin Pharmacol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
Antoinette R Tan, Darlene G Gibbon, Mark N Stein, Diana Lindquist, Jeffery W Edenfield, Jeffrey Botbyl

Cancer Chemother Pharmacol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.
Ruth Plummer, Ayman Madi, Melinda Jeffels, Heike Richly, Bahar Nokay, Jeffrey Botbyl

Cancer Chemother Pharmacol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer.
Vincent Chung, Elisabeth I Heath, William R Schelman, Brendan M Johnson, Lyndon C Kirby, Jeffrey D Botbyl

Cancer Chemother Pharmacol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In response to "Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort".
Angela DeMichele, Phyllis Gimotty, Jeffrey Botbyl, Richard Aplenc, Theresa Colligon

J Clin Oncol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor vascular proteins as biomarkers in ovarian cancer.
Ronald J Buckanovich, Dimitra Sasaroli, Anne O'Brien-Jenkins, Jeffrey Botbyl, Rachel Hammond

J Clin Oncol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of high-risk patients among those diagnosed with thin cutaneous melanomas.
Phyllis A Gimotty, David E Elder, Douglas L Fraker, Jeffrey Botbyl, Kimberly Sellers

J Clin Oncol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technetium Tc 99m sestamibi sensitivity in oxyphil cell-dominant parathyroid adenomas.
Benjamin S Bleier, Virginia A LiVolsi, Ara A Chalian, Phyllis A Gimotty, Jeffrey D Botbyl

Arch Otolaryngol Head Neck Surg· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment.
Ronald J Buckanovich, Dimitra Sasaroli, Ann O'brien-Jenkins, Jeffrey Botbyl, Josè R Conejo-Garcia

Cancer Biol Ther· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of regional nodal disease in patients with thin melanomas.
Giorgos C Karakousis, Phyllis A Gimotty, Jeffrey D Botbyl, Susan B Kesmodel, David E Elder

Ann Surg Oncol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population-based validation of the American Joint Committee on Cancer melanoma staging system.
Phyllis A Gimotty, Jeffrey Botbyl, Seng-Jaw Soong, Dupont Guerry

J Clin Oncol· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.
Angela DeMichele, Richard Aplenc, Jeffrey Botbyl, Theresa Colligan, Lisa Wray

J Clin Oncol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas.
Susan B Kesmodel, Giorgos C Karakousis, Jeffrey D Botbyl, Robert J Canter, Robert T Lewis

Ann Surg Oncol· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis